Psychedelic-assisted therapy shows promise, but evidence remains uneven, review finds
A scoping review of 2020–2025 research finds the strongest psychedelic-assisted therapy evidence in MDMA for PTSD and psilocybin for depression, while flagging blinding problems, psychotherapy variability, and unresolved safety and ethical questions.
Read moreDetails

